NCT03319719View on ClinicalTrials.gov

Evaluation of Pain With Belotero® Balance With Integral Lidocaine for Correction of the Nasolabial Folds

NACompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 18, 2017

Primary Completion Date

December 6, 2017

Study Completion Date

December 6, 2017

Conditions
Correction of Moderate to Severe Nasolabial Folds
Interventions
DEVICE

Belotero® Balance with integral lidocaine

Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.

DEVICE

Belotero® Balance

Mode of application: intradermal injection. Maximum treatment volume: 3 mL per nasolabial fold over two Treatment sessions.

Trial Locations (3)

20037

Center for Dermatology and Dermatology Surgery; Merz Investigational Site #0010170, Washington D.C.

37215

Tennessee Clinical Research Center; Merz Investigational Site #0010097, Nashville

75093

Research Across America (Synexus); Merz Investigational Site #0010125, Plano

All Listed Sponsors
lead

Merz North America, Inc.

INDUSTRY

NCT03319719 - Evaluation of Pain With Belotero® Balance With Integral Lidocaine for Correction of the Nasolabial Folds | Biotech Hunter | Biotech Hunter